Cerecor Inc. (CERC) and Genprex Inc. (NASDAQ:GNPX) Comparing side by side

Since Cerecor Inc. (NASDAQ:CERC) and Genprex Inc. (NASDAQ:GNPX) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerecor Inc. 15.58M 11.95 41.68M -1.05 0.00
Genprex Inc. N/A 0.00 9.61M -0.71 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Cerecor Inc. and Genprex Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Cerecor Inc. -267.52% -164.9% -63.2%
Genprex Inc. 0.00% -163.8% -144.6%

Liquidity

The Current Ratio and Quick Ratio of Cerecor Inc. are 0.7 and 0.7 respectively. Its competitor Genprex Inc.’s Current Ratio is 18.9 and its Quick Ratio is 18.9. Genprex Inc. can pay off short and long-term obligations better than Cerecor Inc.

Institutional and Insider Ownership

The shares of both Cerecor Inc. and Genprex Inc. are owned by institutional investors at 49.9% and 8.8% respectively. Insiders owned roughly 4.1% of Cerecor Inc.’s shares. Insiders Competitively, owned 58.32% of Genprex Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerecor Inc. -4.56% -25.39% -27.02% -20.62% 105.53% 4.69%
Genprex Inc. -23.03% -24.52% -46.82% -87.9% 0% -75.11%

For the past year Cerecor Inc. has 4.69% stronger performance while Genprex Inc. has -75.11% weaker performance.

Summary

Genprex Inc. beats on 5 of the 9 factors Cerecor Inc.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. Genprex, Inc. was founded in 2009 and is based in Austin, Texas.